Home › NDC Lookup › Ingredients › Benzoyl Peroxide › 45802-0101-96
benzoyl peroxide 2.5 g/100g Gel — NDC 45802-0101-96 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

benzoyl peroxide 2.5 g/100g Gel — NDC 45802-101-96 (Billing 45802-0101-96)

by Padagis Israel Pharmaceuticals Ltd · 1 TUBE in 1 CARTON / 60 g in 1 TUBE

This is a package of benzoyl peroxide 2.5 g/100g Gel from Padagis Israel Pharmaceuticals Ltd, marketed since Mar 2012 and currently FDA-listed; retail pharmacies pay about $0.2009 per g (NADAC). It is this product's only package size.

NDC 45802-0101-96
🏷️ FDA NDC (as labeled) 45802-101-96 billing pads the product segment with a zero
OTC On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

⚠️
Other active recalls for Benzoyl Peroxide (different manufacturers) — 1 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Feb 24, 2025 — Chemical Contamination: Presence of benzene. (Denison Pharmaceuticals, LLC) · FDA recall D-0273-2025
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 45802-101-96
Product NDC 45802-101
11-digit billing NDC 45802010196
NCPDP billing unit GM — per gram (weight)
RxCUI 308689
UNII W9WZN9A0GM
Application # M006
SPL Set ID 0ba5e88c-a4d5-4550-93fa-d3d7fee45f9f
DEA schedule Non-controlled
Marketing category OTC MONOGRAPH DRUG
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2012-03-13
Route TOPICAL
Dosage form GEL
Substance BENZOYL PEROXIDE

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 90050010004005
GPI class Benzoyl Peroxide
GCN Seq No 005811
GCN 22932
HICL code 002470
Ingredient (HICL) Benzoyl Peroxide
HIC1 code L
Therapeutic class — broad (HIC1) Skin/Subcutaneous Tissue
HIC2 code L5
Therapeutic class — intermediate (HIC2) Keratolytics/Keratoplastics
HIC3 code L5A
Therapeutic class — specific (HIC3) Keratolytics
AHFS code 84:28.00.00
AHFS class Keratolytic Agents
FDB label name BENZOYL PEROXIDE 2.5% GEL
FDB brand name Benzoyl Peroxide
Legend status O — Over-the-counter (OTC) drug or device
Quick answers
  • GSN (GCN sequence number): 005811
  • GCN: 22932
  • GPI-14 (Medi-Span): 90050010004005
  • HICL (First Databank): 002470
  • AHFS class code: 84:28.00.00
  • RxCUI (RxNorm): 308689
Why two NDCs? The FDA registers this code as 45802-101-96 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 45802-0101-96. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Peroxides class.

Drug family (ATC) Peroxides
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name BENZOYL PEROXIDE 2.5% GEL Ingredient Benzoyl Peroxide
📖 What it is MedlinePlus · NLM

Benzoyl peroxide is used to treat mild to moderate acne.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • Most products are for acne. They dry up pimples and help prevent new ones. Epsolay is a prescription cream for rosacea bumps in adults. The Folliculitis Treatment Cream products ar...
  • For many acne products, start with once a day. You can move up to two or three times daily if your skin tolerates it. If you get dryness or peeling, cut back to once daily or every...
  • Redness, dryness, peeling, itching, and stinging or burning are the usual ones. Using less often can help. Using another acne product at the same time makes irritation more likely.
  • Stop if irritation gets severe. Stop right away and get help if you have hives, swelling or trouble breathing. Those can be signs of a serious allergic reaction.
📖 Read our full Benzoyl Peroxide guide →

Supplement & herbal interactions

Some supplements/herbs that may interact with Benzoyl Peroxide — tap one for details:

Dimethylsulfoxide (dmso)Moderate Turpentine OilModerate AlchemillaMinor
🌿 Every supplement checked against Benzoyl Peroxide (3 interactions) — ranked by severity →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer gPer package
Retail pharmacies payNADAC · weekly $0.201 $12.05 / 60 g
Medicaid paysCMS SDUD · 12 mo $0.2945 $17.67 / 60 g
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per g) — tap or hover for the price & month
Dec 2021 Aug 2022 Jan 2026 Sep 2026 $0.221 $0.180
▲ Up 4% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
45802-0101-96 You're viewing this Main listing 1 TUBE in 1 CARTON / 60 g in 1 TUBE 2012-03-13 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Rugby Benzoyl Peroxide Acne Medication 25 mg/g 00536-1466-25 Rugby 1 tube $0.201 — Availability likely —
benzoyl peroxide 2.5 g/100gthis 45802-0101-96 Padagis 1 tube $0.201 — Availability likely —
Proactiv plus Pore Targeting Treatment 2.5 g/100mL 11410-0046-00 Alchemee, 1 bottle — — FDA listed —
Neutrogena Stubborn Acne AM Treatment 25 mg/g 69968-0653-01 Kenvue 12 tubes — — FDA listed —
2.5 Acne Med 25 mg/mL 70707-0152-15 Face 1 tube — — FDA listed —
Acne Med 2.5% 25 mg/mL 70707-0200-15 Face 1 bottle — — FDA listed —
Touch Acne Treatment Benzoyl Peroxide 25 mg/g 73246-0001-01 Diractions 227 g — — FDA listed —
Rugby Benzoyl Peroxide Acne Medication 25 mg/g 75376-0466-25 Guangzhou 1 tube — — FDA listed —
Biba Acne 2.5 g/100mL 83834-0001-01 Esthetic 30 ml — — Discontinued —
Spot Acne Treatment 0.75Oz 2.5 g/100g 57337-0149-01 Rejoice 1 tube — — FDA listed —
Spot Acne Treatment 0.75Oz 2.5 g/100g 58503-0168-01 China 1 tube — — FDA listed —
Clearogen 3 2.5 g/100g 62742-4238-01 Allure 55 g — — FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2012
On the market since
Mar 2012
📍
2026
Currently FDA-listed
14 years listed
🔒
·
No generic listed yet
brand only
ℹ️No FDA-approved generic found

We did not find an FDA-approved generic match for this exact strength, form and route.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII 92RU3N3Y1O
    Dimethicone is a silicone-based oil that acts as an anti-foaming agent and lubricant in medicines. It reduces gas bubbles in liquid formulations and helps coat and protect the stomach lining when ingested.
  • UNII P160Q81342
    A synthetic cleaning agent derived from lauryl alcohol and succinic acid. It acts as a surfactant and emulsifier to help blend oil and water components, and may aid in drug dissolution and absorption in liquid or semi-solid formulations.
  • UNII 7FLD91C86K
    Edetate disodium is a chemical compound that binds and removes certain metal ions. In medicines, it acts as a preservative and stabilizer by preventing metals like calcium from interfering with the product's shelf life and consistency.
  • UNII PDC6A3C0OX
    Glycerin is a clear, thick liquid derived from plant oils or fats. It acts as a humectant to retain moisture, a sweetener, and a solvent in medications.
  • UNII A2I8C7HI9T
    Methylparaben is a preservative derived from benzoic acid that prevents growth of bacteria, fungi, and mold in medicines. It extends the product's shelf life and maintains safety during storage.
  • UNII JX0HIX6OAG
    Poloxamer 182 is a synthetic polymer made from ethylene oxide and propylene oxide. It acts as a solubilizer and emulsifier, helping mix water and oil-based ingredients together in liquid medications.
  • UNII ETJ7Z6XBU4
    Silicon dioxide is a naturally occurring mineral used as a glidant and anti-caking agent. It helps powder ingredients flow smoothly and prevents clumping during manufacturing and storage.
  • UNII 55X04QC32I
    A strong alkaline chemical used to adjust and maintain the pH balance of liquid medicines. It helps keep the medicine stable and ensures it stays effective during storage.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

9 inactive ingredients listed in the exact product block matched to this NDC.

The official label also statescarbomer homopolymer, dimethicone, disodium lauryl sulfosuccinate, edetate disodium, glycerin, methylparaben, poloxamer 182, purified water, silicon dioxide, sodium hydroxide

Label-section wording can be broader than the structured product block and may mention additional formulation ingredients.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerPadagis Israel Pharmaceuticals Ltd
FDA applicationM006 (OTC MONOGRAPH DRUG)
Labeler code45802
First marketedMar 2012
Product typeHuman Otc Drug
Portfolio175 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

FDA label — Drug Facts FDA SPL

The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⚠️ Warnings 📦 Storage and Handling 🧪 Active Ingredient 🧪 Inactive Ingredients 🎯 Purpose 📄 Do Not Use 📄 Ask a Doctor Before Use If 📄 When Using This Product 📄 Keep Out of Reach of Children 📄 Questions or Comments 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 6 words ▾

Use for the treatment of acne

⏱️ Dosage and Administration 128 words ▾

Directions • Sensitivity Test for a New User. Apply product sparingly to one or two small affected areas during the first 3 days. If no discomfort occurs, follow the directions stated below. • clean the skin thoroughly before applying this product • cover the entire affected area with a thin layer one to three times daily • because excessive drying of the skin may occur, start with one application daily, then gradually increase to two or three times daily if needed or as directed by a doctor • if bothersome dryness or peeling occurs, reduce application to once a day or every other day • if going outside, apply sunscreen after using this product.

If irritation or sensitivity develops, stop use of both products and ask a doctor.

⚠️ Warnings 151 words ▾

Warnings For external use only Do not use if you • have very sensitive skin • are sensitive to benzoyl peroxide When using this product • skin irritation and dryness is more likely to occur if you use another topical acne medication at the same time. If irritation occurs, only use one topical acne medication at a time. • avoid unnecessary sun exposure and use a sunscreen • avoid contact with the eyes, lips, and mouth • avoid contact with hair and dyed fabrics, which may be bleached by this product • skin irritation may occur, characterized by redness, burning, itching, peeling, or possibly swelling.

Irritation may be reduced by using the product less frequently or in a lower concentration. Stop use and ask a doctor if • irritation becomes severe Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.

(1-800-222-1222)

📦 Storage and Handling 7 words ▾

Other information • store at 20°-25° (68°-77°F)

🧪 Active Ingredient 5 words ▾

Active ingredient Benzoyl peroxide 2.5%

🧪 Inactive Ingredients 20 words ▾

Inactive ingredients carbomer homopolymer, dimethicone, disodium lauryl sulfosuccinate, edetate disodium, glycerin, methylparaben, poloxamer 182, purified water, silicon dioxide, sodium hydroxide

🎯 Purpose 3 words ▾

Purpose Acne treatment

📄 Do Not Use 16 words ▾

Do not use if you • have very sensitive skin • are sensitive to benzoyl peroxide

📄 Ask a Doctor Before Use If 11 words ▾

Stop use and ask a doctor if • irritation becomes severe

📄 When Using This Product 99 words ▾

When using this product • skin irritation and dryness is more likely to occur if you use another topical acne medication at the same time. If irritation occurs, only use one topical acne medication at a time. • avoid unnecessary sun exposure and use a sunscreen • avoid contact with the eyes, lips, and mouth • avoid contact with hair and dyed fabrics, which may be bleached by this product • skin irritation may occur, characterized by redness, burning, itching, peeling, or possibly swelling. Irritation may be reduced by using the product less frequently or in a lower concentration.

📄 Keep Out of Reach of Children 20 words ▾

Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away. (1-800-222-1222)

📄 Questions or Comments 4 words ▾

Questions or comments? 1-866-634-9120

📄 Package Label / Principal Display Panel 21 words ▾

Package/Label Principal Display Panel NDC 45802-101-96 Benzoyl Peroxide 2.5% Aqueous Base, Acne Treatment Gel NET WT

2.1 OZ (60 g) carton

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
21.4K
Units reimbursed last 4 qtrs
1.3M
Gross reimbursed last 4 qtrs
$376.3K
Avg / prescription
$17.59
Avg / unit
$0.2945
Latest quarter Q1 2026
4.8KRx
Medicaid pays / g
$0.2945
gross reimbursed
vs
NADAC / g
$0.2009
acquisition cost
=
Spread
+$0.0936
+47% vs cost
What Medicaid paid per g (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
37% FFS 63% MCO
Fee-for-service · 7,958 Rx Managed care · 13,427 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: 18,960 units · 330 per 100k residents MN Wisconsin: 55,080 units · 932 per 100k residents WI Michigan: 2,280 units · 22.7 per 100k residents MI New York: 261,891 units · 1,338 per 100k residents NY Vermont: 780 units · 121 per 100k residents VT New Hampshire: no data reported NH Oregon: 2,370 units · 56.0 per 100k residents OR Nevada: 28,500 units · 892 per 100k residents NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: 15,780 units · 126 per 100k residents IL Indiana: 12,060 units · 176 per 100k residents IN Ohio: 90,600 units · 769 per 100k residents OH Pennsylvania: 64,020 units · 494 per 100k residents PA New Jersey: 137,205 units · 1,477 per 100k residents NJ Massachusetts: 47,503 units · 679 per 100k residents MA California: 84,780 units · 218 per 100k residents CA Utah: no data reported UT Colorado: no data reported CO Nebraska: 4,560 units · 231 per 100k residents NE Missouri: no data reported MO Kentucky: 58,380 units · 1,290 per 100k residents KY West Virginia: 14,160 units · 800 per 100k residents WV Virginia: 24,342 units · 279 per 100k residents VA Maryland: 61,557 units · 996 per 100k residents MD Connecticut: 23,640 units · 654 per 100k residents CT Rhode Island: 4,800 units · 438 per 100k residents RI Arizona: 2,280 units · 30.7 per 100k residents AZ New Mexico: 13,140 units · 622 per 100k residents NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: 18,915 units · 265 per 100k residents TN North Carolina: no data reported NC South Carolina: 15,780 units · 294 per 100k residents SC Delaware: 1,320 units · 128 per 100k residents DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: 6,051 units · 206 per 100k residents MS Alabama: no data reported AL Georgia: 57,660 units · 523 per 100k residents GA D.C.: 5,220 units · 769 per 100k residents DC Hawaii: 20,700 units · 1,443 per 100k residents HI Texas: 123,178 units · 404 per 100k residents TX Florida: no data reported FL
Units reimbursed · per 100k residents
22.71,477
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 New Jersey 1,477 /100k
2 Hawaii 1,443 /100k
3 New York 1,338 /100k
4 Kentucky 1,290 /100k
5 Maryland 996 /100k
6 Wisconsin 932 /100k
7 Nevada 892 /100k
8 West Virginia 800 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Epsolay (matched by generic name) — the program that covers self-administered drugs. 1 manufacturer.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Epsolay. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$60.9K
Claims incl. refills
82
Beneficiaries
63
Spend / beneficiary
$967.04
Spend / claim
$742.97
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
← 45802-0098-28 · Padagis 45802-0102-84 · Padagis →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.